Curatis

Update in progress

CURN.SW (Swiss)

Curatis Holding AG acquires, develops, and commercializes medicines for the prevention, diagnosis, and treatment of rare and specialty diseases. Its portfolio spans analgesia, cardiovascular, oncology, ophthalmology, infectious and immunology areas, among others. It also develops C-PTBE-01 (Phase IIb) for peritumoral brain edema; C-AM-01 (Phase IIa) for severe migraine with aura; C-MOH-01 (Phase IIa) for medication-overuse headache; and C-FI-01 (Phase I) for fibrotic or inflammatory orphan diseases. Founded 2002, Liestal, Switzerland.